Literature DB >> 12183657

Differential effects of mu-opioid receptor ligands on Ca(2+) signaling.

J Mark Quillan1, Kurt W Carlson, Chunyan Song, Danxin Wang, Wolfgang Sadée.   

Abstract

Activation of mu-opioid receptors (MORs) transfected into human embryonic kidney 293 cells, caused a multiphasic increase in cytosolic free Ca(2+) levels (Ca(2+)i). The first Ca(2+)i maximum (peak 1) between 5 and 7 s depended on the presence of extracellular Ca(2+) (Ca(2+)e). The second phase peaking at approximately 15 s (peak 2) was independent of Ca(2+)e and thus represents Ca(2+) release from intracellular stores. A decrease in temperature from 37 to 25 degrees C also caused reduction of peak 1 but not peak 2, suggesting that the two responses arise from mechanistically distinct pathways. A delayed Ca(2+)e-dependent third response phase is thought to represent capacitative Ca(2+)e influx evoked after release of Ca(2+) from internal stores. Agonists and antagonists of two major classes of opioid ligands, oxymorphinans (morphine and naloxone) and oripavines (etorphine and diprenorphine), had differential effects on Ca(2+) currents. Although morphine activated both phases with equal potency, etorphine was 20-fold less potent at stimulating peak 1 over peak 2. Similarly, the antagonists, naloxone and diprenorphine, blocked the Ca(2+) response to each agonist with greatly varying potencies. Specifically, concomitant injection of diprenorphine failed to affect peak 1 (thought to represent rapid Ca(2+)e influx) stimulated by morphine while fully blocking peak 2 (intracellular Ca(2+) release). However, diprenorphine potently inhibited peak 1 as well when added to the cells before morphine, indicating limited or slow access of diprenorphine to these morphine binding sites. The existence of multiple, functionally distinct binding site conformations could account for these findings. In conclusion, different opioid ligands can differentially affect Ca(2+) response patterns resulting from MOR activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12183657     DOI: 10.1124/jpet.302.3.1002

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance.

Authors:  Kirsten M Raehal; Cullen L Schmid; Chad E Groer; Laura M Bohn
Journal:  Pharmacol Rev       Date:  2011-08-26       Impact factor: 25.468

2.  GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity.

Authors:  Ruturaj R Masvekar; Nazira El-Hage; Kurt F Hauser; Pamela E Knapp
Journal:  Mol Cell Neurosci       Date:  2015-01-20       Impact factor: 4.314

3.  Ca2+/calmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia.

Authors:  Yan Chen; Cheng Yang; Zaijie Jim Wang
Journal:  J Neurosci       Date:  2010-01-06       Impact factor: 6.167

4.  The Chemical Interplay between Nitric Oxide and Mitochondrial Cytochrome c Oxidase: Reactions, Effectors and Pathophysiology.

Authors:  Paolo Sarti; Elena Forte; Alessandro Giuffrè; Daniela Mastronicola; Maria Chiara Magnifico; Marzia Arese
Journal:  Int J Cell Biol       Date:  2012-07-01

5.  Global changes in the rat heart proteome induced by prolonged morphine treatment and withdrawal.

Authors:  Zdenka Drastichova; Jitka Skrabalova; Petr Jedelsky; Jan Neckar; Frantisek Kolar; Jiri Novotny
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

Review 6.  Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.

Authors:  Wolfgang Sadee; John Oberdick; Zaijie Wang
Journal:  Molecules       Date:  2020-09-11       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.